Inhibitor of nuclear factor kappa-B kinase complex and NF-kappa-B-inducing kinase (IKK complex and NIK)

The IKK complex and NIK (NF-kappa-B-inducing kinase) are central enzymatic components of the NF-kappa-B signaling pathway, which regulates critical processes such as immune response, inflammation, and cell survival (Nature Reviews Immunology, 2017). The IKK complex is typically a heterotrimer consisting of two catalytic kinases, IKK-alpha (CHUK) and IKK-beta (IKBKB), and a regulatory subunit, IKK-gamma (NEMO/IKBKG), which primarily drives the canonical NF-kappa-B pathway (UniProt: O15111, O14920). NIK (MAP3K14) is a serine/threonine kinase that serves as the master regulator of the non-canonical NF-kappa-B pathway by activating IKK-alpha homodimers (UniProt: Q99558). Dysregulation or constitutive activation of these kinases is implicated in a wide range of pathologies, including chronic inflammatory diseases like rheumatoid arthritis and various hematological malignancies such as multiple myeloma and B-cell lymphomas (Cell Death & Disease, 2018). Pharmacological strategies focus on small molecule inhibitors that block the kinase activity of IKK-beta or NIK to prevent the nuclear translocation of NF-kappa-B transcription factors and the subsequent expression of pro-inflammatory and anti-apoptotic genes. However, the clinical utility of these inhibitors has been limited by significant safety concerns, including severe immunosuppression and systemic toxicity, due to the essential role of NF-kappa-B in maintaining normal physiological functions and host defense (Journal of Clinical Investigation, 2012).

Other names

IKK/NIKNF-kappa-B signaling kinasesCHUK/IKBKB/IKBKG and MAP3K14Inhibitor of nuclear factor kappa-B kinase and Mitogen-activated protein kinase kinase kinase 14

Inhibition of the catalytic activity of IKK-beta or NIK to prevent the phosphorylation of IκB proteins or p100, respectively, thereby blocking the nuclear translocation of NF-κB transcription factors and subsequent gene expression.